Antibodies, Monoclonal
"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
Descriptor ID |
D000911
|
MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1981 | 2 | 2 | 4 | 1982 | 6 | 5 | 11 | 1983 | 13 | 6 | 19 | 1984 | 10 | 14 | 24 | 1985 | 9 | 8 | 17 | 1986 | 5 | 15 | 20 | 1987 | 16 | 20 | 36 | 1988 | 15 | 17 | 32 | 1989 | 7 | 17 | 24 | 1990 | 9 | 13 | 22 | 1991 | 9 | 11 | 20 | 1992 | 5 | 17 | 22 | 1993 | 4 | 19 | 23 | 1994 | 12 | 12 | 24 | 1995 | 7 | 16 | 23 | 1996 | 4 | 12 | 16 | 1997 | 4 | 8 | 12 | 1998 | 6 | 17 | 23 | 1999 | 11 | 18 | 29 | 2000 | 9 | 12 | 21 | 2001 | 15 | 21 | 36 | 2002 | 11 | 16 | 27 | 2003 | 15 | 15 | 30 | 2004 | 22 | 18 | 40 | 2005 | 25 | 19 | 44 | 2006 | 27 | 17 | 44 | 2007 | 31 | 15 | 46 | 2008 | 25 | 21 | 46 | 2009 | 33 | 19 | 52 | 2010 | 41 | 26 | 67 | 2011 | 22 | 14 | 36 | 2012 | 27 | 12 | 39 | 2013 | 24 | 10 | 34 | 2014 | 29 | 13 | 42 | 2015 | 15 | 11 | 26 | 2016 | 25 | 9 | 34 | 2017 | 31 | 11 | 42 | 2018 | 27 | 15 | 42 | 2019 | 23 | 13 | 36 | 2020 | 15 | 15 | 30 | 2021 | 10 | 20 | 30 | 2022 | 3 | 11 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Lafeuille MH, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 Jul 05; 27(7):e589-e596.
-
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030.
-
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046.
-
McDonald BD, Dyer EC, Rubin DT. IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
-
Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees P. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022 04 13; 12(4):63.
-
Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 Jul; 11(14):2790-2800.
-
Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist. 2022 03 11; 27(3):e223-e232.
-
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 04; 7(2):100408.
-
McGregor B, O'Donnell PH, Balar A, Petrylak D, Rosenberg J, Yu EY, Quinn DI, Heath EI, Campbell M, Hepp Z, McKay C, Steinberg J, Regnault A, Mazerolle F, Galsky MD. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. Eur Urol. 2022 05; 81(5):515-522.
-
Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroglu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 04 20; 40(12):1301-1311.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|